<DOC>
	<DOCNO>NCT00876863</DOCNO>
	<brief_summary>The purpose study evaluate potential benefit CERE-110 treatment Alzheimer 's disease . CERE-110 experimental drug design help nerve cell brain function well . CERE-110 us virus transfer gene make Nerve Growth Factor ( NGF ) , protein may make nerve cell brain healthier protect die . The virus use CERE-110 cause disease people . CERE-110 carefully study laboratory animal early stage test people . Fifty patient mild moderate Alzheimer 's disease participate study . Half study subject CERE-110 inject brain surgical procedure , half undergo `` placebo '' surgery medication inject . All study participant follow least two year surgery .</brief_summary>
	<brief_title>Randomized , Controlled Study Evaluating CERE-110 Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis mild moderate Alzheimer 's disease Approved medication Alzheimer 's disease may take dose stable 3 month A study partner attend study visit Good general health Medically able undergo neurosurgery Significant neurological disease Alzheimer 's disease Significant depression psychiatric disorder Unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Memory loss</keyword>
	<keyword>Cognitive impairment</keyword>
	<keyword>Nerve growth factor</keyword>
	<keyword>NGF</keyword>
	<keyword>Neurotrophic factor</keyword>
	<keyword>Gene therapy</keyword>
</DOC>